argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

manilatimes.net

Image Credit: manilatimes.net

Please find more details at manilatimes.net

Summary

Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three su…

Source: manilatimes.net

Read More

(0)

Exclusive AI-Powered News Insights (For Members only)

Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!